Ming Luo

Dr. Ming Luo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2009 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
DWDu Wenqi
Du Wenqi
WLWang Li
Wang Li
CSCao Shanshan
Cao Shanshan
CBChen Bei
Chen Bei
ZYZhang Yafei
Zhang Yafei
MDMingfan Dai
Mingfan Dai

1 November 2011 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MLMing Luo
Ming Luo
LLLei Li
Lei Li
CLChen-Zheng Lu
Chen-Zheng Lu
WCWu-Kui Cao
Wu-Kui Cao
To evaluate the clinical efficacy of lactulose in patients with minimal hepatic encephalopathy (MHE). Randomized controlled trials (RCTs) comparing lactulose with placebo or with no intervention in the management of MHE that were conducted from January 1990 to July 2011 were searched from MEDLINE, EMBASE, SCI, Cochrane Controlled Trials Register, and China Biological Medicine Database. Studies with a Jadad score higher than 3 were included in the meta-analysis and evaluated using RevMan5.0 software for relative risk (RR) or weighted mean difference (WMD) with 95% confidence intervals (95% CI). Sensitivity analysis was performed on the ethnical differences and quality of the trials. Publication bias was observed using an inverted funnel plot. Nine studies with 434 patients were included in the meta-analysis. Compared with placebo or no intervention, lactulose significantly reduced the risk of no improvement in neuropsychological tests (RR: 0.52, 95% CI: 0.44-0.62, P<0.00001), the time required for the completion of the number connection test-A (WMD: -26.95, 95% CI: -37.81 to -16.10, P<0.00001), and the mean number of abnormal neuropsychological tests (WMD: -1.76, 95% CI: -1.96 to -1.56, P<0.00001). Furthermore, the meta-analysis also showed that lactulose prevented the progression to overt hepatic encephalopathy (RR: 0.17, 95% CI: 0.06-0.52, P=0.002), reduced blood ammonia levels (WMD: -9.89 µmol/l, 95% CI: -11.01 to -8.77 µmol/l, P<0.00001), and improve health-related quality of life (WMD: -6.05, 95% CI: -6.30 to -5.20, P<0.00001). However, no significant difference was observed in the mortality of patients with MHE (RR: 0.75, 95% CI: 0.21-2.72, P=0.66), and lactulose significantly increased the incidence of diarrhea (RR: 4.38, 95% CI: 1.35-14.25, P=0.01). Lactulose has significant beneficial effects for patients with MHE compared with placebo or no intervention.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MLMing Luo
Ming Luo
JGJian-Yang Guo
Jian-Yang Guo
WCWu-Kui Cao
Wu-Kui Cao
Hepatic encephalopathy (HE) is a severe neuropsychiatric syndrome that most commonly occurs in decompensated liver cirrhosis and incorporates a spectrum of manifestations that ranges from mild cognitive impairment to coma. Although the etiology of HE is not completely understood, it is believed that multiple underlying mechanisms are involved in the pathogenesis of HE, and one of the main factors is thought to be ammonia; however, the ammonia hypothesis in the pathogenesis of HE is incomplete. Recently, it has been increasingly demonstrated that inflammation, including systemic inflammation, neuroinflammation and endotoxemia, acts in concert with ammonia in the pathogenesis of HE in cirrhotic patients. Meanwhile, a good number of studies have found that current therapies for HE, such as lactulose, rifaximin, probiotics and the molecular adsorbent recirculating system, could inhibit different types of inflammation, thereby improving the neuropsychiatric manifestations and preventing the progression of HE in cirrhotic patients. The anti-inflammatory effects of these current therapies provide a novel therapeutic approach for cirrhotic patients with HE. The purpose of this review is to describe the inflammatory mechanisms behind the etiology of HE in cirrhosis and discuss the current therapies that target the inflammatory pathogenesis of HE.

7 January 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MLMing Luo
Ming Luo
RXRui-Juan Xin
Rui-Juan Xin
FHFang-Rui Hu
Fang-Rui Hu
LYLi Yao
Li Yao
SHSheng-Juan Hu
Sheng-Juan Hu
FBFeihu Bai
Feihu Bai
Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis

1 August 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
DZDaya Zhang
Daya Zhang
ZLZhengJin Liu
ZhengJin Liu
FBFeihu Bai
Feihu Bai
Alcoholic liver disease (ALD)—one of the most common liver diseases — involves a wide range of disorders, including asymptomatic hepatic steatosis, alcoholic hepatitis (AH), liver fibrosis, and cirrhosis. Alcohol consumption induces a weakened gut barrier and changes in the composition of the gut microbiota. The presence of CYP2E1 and its elevated levels in the gastrointestinal tract after alcohol exposure lead to elevated levels of ROS and acetaldehyde, inducing inflammation and oxidative damage in the gut. At the same time, the influx of harmful molecules such as the bacterial endotoxin LPS and peptidogly from gut dysbiosis can induce intestinal inflammation and oxidative damage, further compromising the intestinal mucosal barrier. In this process, various oxidative stress-mediated post-translational modifications (PTMs) play an important role in the integrity of the barrier, eg, the presence of acetaldehyde will result in the sustained phosphorylation of several paracellular proteins (occludin and zona occludens-1), which can lead to intestinal leakage. Eventually, persistent oxidative stress, LPS infiltration and hepatocyte damage through the enterohepatic circulation will lead to hepatic stellate cell activation and hepatic fibrosis. In addition, probiotics, prebiotics, synbiotics, fecal microbial transplantation (FMT), bioengineered bacteria, gut-restricted FXR agonists and others are promising therapeutic approaches that can alter gut microbiota composition to improve ALD. In the future, there will be new challenges to study the interactions between the genetics of individuals with ALD and their gut microbiome, to provide personalized interventions targeting the gut-liver axis, and to develop better techniques to measure microbial communities and metabolites in the body.

1 December 2016 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
RXRuijuan Xin
Ruijuan Xin
FBFeihu Bai
Feihu Bai
YFYaning Feng
Yaning Feng
MJMengna Jiu
Mengna Jiu
XLXiaogang Liu
Xiaogang Liu
DFDaiming Fan
Daiming Fan